Antibody profiling offers deep insights into underlying pathogenic mechanisms, revealing disease subtypes and predicting treatment responses. This information enhances patient stratification, optimizing clinical trial selection and improving treatment outcomes.
By analyzing multiple autoantibody targets in a single assay, Sengenics technology accelerates the identification and validation of biomarker signatures.
Sengenics drives biomarker discovery for patient stratification with advanced, highly multiplexed protein microarrays. Our technology ensures precise, reproducible detection of disease-relevant autoantibody signatures from patient plasma or serum.
Patient Stratification in Systemic Lupus Erythematosus (SLE)
Heatmap showing unsupervised hierarchical clustering of 79 validated autoantibodies in SLE patients from both discovery (n = 186) and validation (n = 91) cohorts. The autoantibodies clustered into four distinct groups, which may represent different molecular sub-types of SLE, each with unique disease trajectories and treatment responses.
Source: M.J. Lewis, et al., Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus, Journal of Autoimmunity (2018).
